PMID- 26803187
OWN - NLM
STAT- MEDLINE
DCOM- 20161107
LR  - 20220321
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 118
IP  - 3
DP  - 2016 Mar
TI  - Acute esophagitis for patients with local-regional advanced non small cell lung 
      cancer treated with concurrent chemoradiotherapy.
PG  - 465-70
LID - S0167-8140(16)00011-6 [pii]
LID - 10.1016/j.radonc.2016.01.007 [doi]
AB  - PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy 
      for local-regional advanced non small cell lung cancer (NSCLC). The purpose of 
      this study was to estimate the dose-effect relationship using clinical and 
      dosimetric parameters in patients receiving intensity modulated radiotherapy 
      (IMRT) and concomitant chemotherapy (CCT). METHODS: Between 2009 and 2013, 117 
      patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized 
      phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. 
      The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. 
      Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 
      esophagitis through logistic regression. RESULTS: Grade 2 esophagitis was 
      experienced by 31 (27%). All models including gender, institution, a dosimetric 
      parameter and a position parameter were significantly associated with 
      esophagitis. The two models using the relative esophagus volume irradiated above 
      40 Gy (V40, OR=2.18/10% volume) or the length of esophagus irradiated above 40 Gy 
      (L40, OR=4.03/5 cm) were optimal. The upper part of esophagus was more sensitive 
      and females experienced more toxicity than men. CONCLUSION: V40 and L40 were most 
      effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of 
      esophagus was more sensitive.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Pan, Yi
AU  - Pan Y
AD  - Department of Radiation Oncology, Guangdong General Hospital & Guangdong Academy 
      of Medical Science, PR China; Institute of Clinical Research, University of 
      Southern Denmark, Odense, Denmark.
FAU - Brink, Carsten
AU  - Brink C
AD  - Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; 
      Laboratory of Radiation Physics, Odense University Hospital, Denmark.
FAU - Knap, Marianne
AU  - Knap M
AD  - Department of Oncology, Aarhus University Hospital, Denmark.
FAU - Khalil, Azza A
AU  - Khalil AA
AD  - Department of Oncology, Aarhus University Hospital, Denmark.
FAU - Nyhus, Christa H
AU  - Nyhus CH
AD  - Department of Oncology, Vejle Hospital, Sygehus Lillebaelt, Denmark.
FAU - McCulloch, Tine
AU  - McCulloch T
AD  - Department of Oncology, Aalborg University Hospital, Denmark.
FAU - Holm, Bente
AU  - Holm B
AD  - Department of Oncology, Herlev University Hospital, Denmark.
FAU - Wu, Yi-long
AU  - Wu YL
AD  - Guangdong Lung Cancer Institute, PR China.
FAU - Schytte, Tine
AU  - Schytte T
AD  - Department of Oncology, Odense University Hospital, Denmark.
FAU - Hansen, Olfred
AU  - Hansen O
AD  - Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; 
      Department of Oncology, Odense University Hospital, Denmark. Electronic address: 
      olfred.hansen@rsyd.dk.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160120
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/radiotherapy/*therapy
MH  - Chemoradiotherapy/*adverse effects
MH  - Dose-Response Relationship, Radiation
MH  - Esophagitis/*etiology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*therapy
MH  - Male
MH  - Middle Aged
MH  - Radiotherapy, Intensity-Modulated/adverse effects
OTO - NOTNLM
OT  - Acute esophagitis
OT  - Concurrent chemoradiotherapy
OT  - IMRT
OT  - Non small cell lung cancer
EDAT- 2016/01/25 06:00
MHDA- 2016/11/08 06:00
CRDT- 2016/01/25 06:00
PHST- 2015/10/04 00:00 [received]
PHST- 2016/01/08 00:00 [revised]
PHST- 2016/01/10 00:00 [accepted]
PHST- 2016/01/25 06:00 [entrez]
PHST- 2016/01/25 06:00 [pubmed]
PHST- 2016/11/08 06:00 [medline]
AID - S0167-8140(16)00011-6 [pii]
AID - 10.1016/j.radonc.2016.01.007 [doi]
PST - ppublish
SO  - Radiother Oncol. 2016 Mar;118(3):465-70. doi: 10.1016/j.radonc.2016.01.007. Epub 
      2016 Jan 20.